BioSpace News Archive

Natus Medical Incorporated announced that the Company will release its 2020 first quarter financial results after the close of the market on Thursday, April 30th.

Ensuring the health and safety of its team members, customers and communities is Walgreens top priority, now more than ever.

Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates, announced that the Company will host a conference call and live audio webcast on Monday, April 6, 2020 at 8:00 a.m. Eastern Time to provide a clinical development and general corporate update.

A well-known market intelligence company, Infiniti Research, has partnered with several global companies across industries to help meet their strategic objectives and implement seamless route-to-market strategies through turnkey solutions.

HealthcareSource, the leading provider of talent management solutions for the healthcare industry, is partnering with Amplifire, an innovative knowledge engineering and training platform, to distribute its Infection Prevention and Control Essentials – Rapid Refresher course to healthcare organizations across the U.S.

CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD will participate in a conference call,

Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of its recent article that examines the role of pharma analytics in enhancing clinical trial outcomes amidst the major outbreak of COVID-19.

Radiation Shield Technologies announced its introduction of Demron C reusable, full-body, anti-viral personal-protective equipment for healthcare workers, first responders, and other high-risk individuals at the frontlines of the Covid-19 pandemic.

“We are grateful for the opportunity to help the health care community as we all continue to adapt to keep pace with the escalating impact of the COVID-19 pandemic,” said Gary M. Reedy, chief executive officer at the American Cancer Society.

Shenogen, today announced that it has entered into an exclusive collaboration and licensing agreement with Shanghai BioArdis Co., Ltd. and BioArdis LLC for the development and commercialization of BioArdis’ novel FGFR4